-
平臺編號：bio-69105
-
國際編號：CRL-1902?
-
細(xì)胞信息： UACC-893
-
規(guī)格：Frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
UACC-893
運(yùn)輸方式：凍存運(yùn)輸
ATCC Number：CRL-1902?
相關(guān)疾?。簩?dǎo)管癌
年限：57 years
細(xì)胞形態(tài)：上皮樣
是否是腫瘤細(xì)胞：1
物種來源：人
生長狀態(tài)：貼壁生長
器官來源：乳房
數(shù)量：大量
規(guī)格：100 ul Designations: UACC-893
Depositors: ?A Liebovitz, J Trent
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: mammary gland; breast
Disease: primary ductal carcinoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The breast carcinoma UACC-893 was deposited in the ATCC by Albert Leibovitz and Jeffrey M. Trent, Arizona Cancer Center, University of Arizona, Tucson, Arizona.These cells are distributed for research purposes only. The University of Arizona releases the line subject to the following: 1. UACC-893 cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of the University of Arizona; 2. Any proposed commercial use of these cells must first be negotiated with The Director of The Arizona Cancer Center, University of Arizona, 1501 N. Campbell Ave., Tucson, AZ 85724. Telephone (602) 626-7925, FAX (602) 626-2284; 3. In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publications (Proc. Am. Assoc. Cancer Res. 29: 24, 1988; Br. J. Cancer 63: 727-735, 1991).
DNA Profile (STR):Amelogenin: X
CSF1PO: 11,12
D13S317: 13
D16S539: 9,13
D5S818: 12
D7S820: 11
THO1: 6,9.3
TPOX: 8
vWA: 16,17
Cytogenetic Analysis:modal number = 62; range = 51 to 65
Age: 57 years
Gender: female
Ethnicity: Caucasian
Comments:This cell line was established by A. Liebovitz and associates in 1987 from breast tissue removed at lumpectomy to remove a ductal carcinoma (stage II). Prior to surgery, the patient had received no chemotherapy.The cells exhibit a 20 fold amplification of the HER-2/neu oncogene sequence. They are negative for estrogen receptors, progesterone receptors and P glycoprotein.The cells grow very slowly, and growth can be enhanced by using 20% fetal bovine serum and adding epidermal growth factor (10 ng/ml) to the medium.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 100%
Temperature: 37.0°C
Subculturing: Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Doubling Time: 100 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2008
recommended serum:ATCC 30-2020
purified DNA:ATCC CRL-1902D
0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101
Cell culture tested DMSO:ATCC 4-X
References: 22207: . . Proc. Am. Assoc. Cancer Res. 29: 24, 1988.
26165: Meltzer P, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63: 727-735, 1991. PubMed: 1674877
ATCC Number：CRL-1902?
相關(guān)疾?。簩?dǎo)管癌
年限：57 years
細(xì)胞形態(tài)：上皮樣
是否是腫瘤細(xì)胞：1
物種來源：人
生長狀態(tài)：貼壁生長
器官來源：乳房
數(shù)量：大量
規(guī)格：100 ul Designations: UACC-893
Depositors: ?A Liebovitz, J Trent
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: mammary gland; breast
Disease: primary ductal carcinoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The breast carcinoma UACC-893 was deposited in the ATCC by Albert Leibovitz and Jeffrey M. Trent, Arizona Cancer Center, University of Arizona, Tucson, Arizona.These cells are distributed for research purposes only. The University of Arizona releases the line subject to the following: 1. UACC-893 cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of the University of Arizona; 2. Any proposed commercial use of these cells must first be negotiated with The Director of The Arizona Cancer Center, University of Arizona, 1501 N. Campbell Ave., Tucson, AZ 85724. Telephone (602) 626-7925, FAX (602) 626-2284; 3. In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publications (Proc. Am. Assoc. Cancer Res. 29: 24, 1988; Br. J. Cancer 63: 727-735, 1991).
DNA Profile (STR):Amelogenin: X
CSF1PO: 11,12
D13S317: 13
D16S539: 9,13
D5S818: 12
D7S820: 11
THO1: 6,9.3
TPOX: 8
vWA: 16,17
Cytogenetic Analysis:modal number = 62; range = 51 to 65
Age: 57 years
Gender: female
Ethnicity: Caucasian
Comments:This cell line was established by A. Liebovitz and associates in 1987 from breast tissue removed at lumpectomy to remove a ductal carcinoma (stage II). Prior to surgery, the patient had received no chemotherapy.The cells exhibit a 20 fold amplification of the HER-2/neu oncogene sequence. They are negative for estrogen receptors, progesterone receptors and P glycoprotein.The cells grow very slowly, and growth can be enhanced by using 20% fetal bovine serum and adding epidermal growth factor (10 ng/ml) to the medium.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 100%
Temperature: 37.0°C
Subculturing: Protocol:
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Doubling Time: 100 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2008
recommended serum:ATCC 30-2020
purified DNA:ATCC CRL-1902D
0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101
Cell culture tested DMSO:ATCC 4-X
References: 22207: . . Proc. Am. Assoc. Cancer Res. 29: 24, 1988.
26165: Meltzer P, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63: 727-735, 1991. PubMed: 1674877
